首页 | 本学科首页   官方微博 | 高级检索  
     


Isoniazid,Pyrazinamide and Rifampicin Content Variation in Split Fixed-Dose Combination Tablets
Authors:Thomas Pouplin  Pham Nguyen Phuong  Pham Van Toi  Julie Nguyen Pouplin  Jeremy Farrar
Affiliation:1. Mahidol University-Oxford Tropical Medicine Research Programme, Faculty of Tropical Medicine, Mahidol University, Rajthevee, Bangkok, Thailand.; 2. Centre for Tropical Medicine, Oxford University Clinical Research Unit Vietnam, Wellcome Trust Major Overseas Programme, Ho Chi Minh City, Vietnam.; 3. Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.; Concordia University Wisconsin, United States of America,
Abstract:

Setting

In most developing countries, paediatric tuberculosis is treated with split tablets leading to potential inaccuracy in the dose delivery and drug exposure. There is no data on the quality of first-line drugs content in split fixed-dose combination tablets.

Objective

To determine Isoniazid, Pyrazinamide and Rifampicin content uniformity in split FDC tablets used in the treatment of childhood tuberculosis.

Design

Drug contents of 15 whole tablets, 30 half tablets and 36 third tablets were analysed by high performance liquid chromatography. The content uniformity was assessed by comparing drug content measured in split portions with their expected amounts and the quality of split portions was assessed applying qualitative specifications for whole tablets.

Results

All whole tablets measurements fell into the USP proxy for the three drugs. But a significant number of half and third portions was found outside the tolerated variation range and the split formulation failed the requirements for content uniformity. To correct for the inaccuracy of splitting the tablets into equal portions, a weight-adjustment strategy was used but this did not improve the findings.

Conclusion

In split tablets the content of the three drugs is non-uniform and exceeded the USP recommendations. There is an absolute need to make child-friendly formulations available for the treatment of childhood tuberculosis.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号